Liposome Mediated-CYP1A1 Gene Silencing Nanomedicine Prepared Using Lipid Film-Coated Proliposomes as a Potential Treatment Strategy of Lung Cancer by Zhang, Mengtian et al.
Article
Liposome Mediated­CYP1A1 Gene Silencing 
Nanomedicine Prepared Using Lipid Film­Coated 
Proliposomes as a Potential Treatment Strategy of 
Lung Cancer
Zhang, Mengtian, Wang, Qin, Wan, Ka-Wai, Ahmed, Waqar, 
Phoenix, David A, Zhang, Zhirong, Elrayess, Mohamed A, Elhissi, 
Abdelbary and Sun, Xun
Available at http://clok.uclan.ac.uk/28588/
Zhang, Mengtian, Wang, Qin, Wan, Ka­Wai, Ahmed, Waqar, Phoenix, David A, Zhang, Zhirong, 
Elrayess, Mohamed A, Elhissi, Abdelbary and Sun, Xun (2019) Liposome Mediated­CYP1A1 Gene  
Silencing Nanomedicine Prepared Using Lipid Film­Coated Proliposomes as a Potential 
Treatment Strategy of Lung Cancer. International Journal of Pharmaceutics, 566 . pp. 185­193. 
ISSN 0378­5173  
It is advisable to refer to the publisher’s version if you intend to cite from the work.
http://dx.doi.org/10.1016/j.ijpharm.2019.04.078
For more information about UCLan’s research in this area go to 
http://www.uclan.ac.uk/researchgroups/ and search for <name of research Group>.
For information about Research generally at UCLan please go to 
http://www.uclan.ac.uk/research/ 
All outputs in CLoK are protected by Intellectual Property Rights law, including
Copyright law.  Copyright, IPR and Moral Rights for the works on this site are retained 
by the individual authors and/or other copyright owners. Terms and conditions for use 
of this material are defined in the http://clok.uclan.ac.uk/policies/
CLoK
Central Lancashire online Knowledge
www.clok.uclan.ac.uk
Accepted Manuscript
Liposome Mediated-CYP1A1 Gene Silencing Nanomedicine Prepared Using
Lipid Film-Coated Proliposomes as a Potential Treatment Strategy of Lung
Cancer
Mengtian Zhang, Qin Wang, Ka-Wai Wan, Waqar Ahmed, David A Phoenix,
Zhirong Zhang, Mohamed A. Elrayess, Abdelbary Elhissi, Xun Sun
PII: S0378-5173(19)30349-7
DOI: https://doi.org/10.1016/j.ijpharm.2019.04.078
Reference: IJP 18326
To appear in: International Journal of Pharmaceutics
Received Date: 19 November 2018
Revised Date: 17 April 2019
Accepted Date: 29 April 2019
Please cite this article as: M. Zhang, Q. Wang, K-W. Wan, W. Ahmed, D.A. Phoenix, Z. Zhang, M.A. Elrayess, A.
Elhissi, X. Sun, Liposome Mediated-CYP1A1 Gene Silencing Nanomedicine Prepared Using Lipid Film-Coated
Proliposomes as a Potential Treatment Strategy of Lung Cancer, International Journal of Pharmaceutics (2019),
doi: https://doi.org/10.1016/j.ijpharm.2019.04.078
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
  
1
1 Liposome Mediated-CYP1A1 Gene Silencing Nanomedicine Prepared 
2 Using Lipid Film-Coated Proliposomes as a Potential Treatment Strategy 
3 of Lung Cancer
4 Mengtian Zhang1, Qin Wang1, Ka-Wai Wan2, Waqar Ahmed3, David A Phoenix4, Zhirong 
5 Zhang1, Mohamed A Elrayess5, Abdelbary Elhissi6*, Xun Sun1**
6 1Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, 
7 West China School of Pharmacy, Sichuan University, Chengdu 610041, PR China
8 2Institute of Nanotechnology and Bioengineering, School of Pharmacy and Biomedical 
9 Sciences, University of Central Lancashire, Preston, UK
10 3Nanoscience Research Group, School of Mathematics and Physics, College of Science, 
11 University of Lincoln, Lincoln LN6 7TS, UK
12 4Office of the Vice Chancellor, London South Bank University, 103 Borough Road, 
13 London SE1 0AA, UK
14 5Anti-Doping Lab Qatar, Sports City, Doha, Qatar
15 6Office of Vice President for Research and Graduate Studies, Qatar University, Doha, 
16 Qatar, and College of Pharmacy, Qatar University, Doha, Qatar
17 *Corresponding author 1
18 Dr. Abdelbary Elhissi
19 Office of Vice President (Research and Graduate Studies) 
20 Qatar University, Doha, Qatar &
21 College of Pharmacy, Qatar University
22 Doha, Qatar, P.O. Box 2713
23 Tel: +974 4403 5632
24 E-mail: aelhissi@qu.edu.qa
25
26
27 **Corresponding author 2
28 Prof. Xun Sun 
  
2
29 West China School of Pharmacy
30 Sichuan University, No. 17, Section 3, Southern Renmin Road
31 Chengdu 610041, People’s Republic of China
32 Tel.: +86 28 85502307
33 Fax: +86 28 85501615
34 E-mail: xunsun22@gmail.com 
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
  
3
64
65 ABSTRACT:
66 The occurrence of lung cancer is linked with tobacco smoking, mainly through the 
67 generation of polycyclic aromatic hydrocarbons (PAHs). Elevated activity of cytochrome 
68 P4501A1 (CYP1A1) plays an important role in the metabolic processing of PAHs and its 
69 carcinogenicity. The present work aimed to investigate the role of CYP1A1 gene in PAH-
70 mediated growth and tumor development in vitro and using an in vivo animal model. RNAi 
71 strategy was utilized to inhibit the overexpression of CYP1A1 gene using cationic 
72 liposomes generated using a lipid film-coated proliposome microparticles. Treatment of 
73 PAH-induced human alveolar adenocarcinoma cell line with cationic liposomes carrying 
74 CYP1A1 siRNA resulted in down regulation of CYP1A1 mRNA, protein as well as its 
75 enzymatic activity, triggering apoptosis and inhibiting multicellular tumor spheroids 
76 formation in vitro. Furthermore, silencing of CYP1A1 gene in BALB/c nude xenografts 
77 inhibited tumor growth via down regulation of CYP1A1 expression. Altogether, our 
78 findings showed that liposome-based gene delivery technology is a viable and stable 
79 approach for targeting cancer causing genes such as CY1PA1. This technology facilitated 
80 by the use of sugar particles coated with lipid films has demonstrated ability to generate 
81 anticancer effects that might be used in the future for therapeutic intervention and treatment 
82 of lung cancer.
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83 KEYWORDS: Apoptosis, Cancer, CYP1A1, Lung, siRNA, Smoking, Tobacco 
84 1. INTRODUCTION
85 Lung cancer has become a leading cause of death worldwide due to the increased 
86 environmental contamination with inhalable carcinogens occurring as byproducts of 
87 combustion processes and unhealthy habits such as tobacco smoking (Field and Withers, 
88 2012). Despite the efforts made to improve the life quality of cancer patients, a proper 
89 understanding of the pathogenesis of lung cancer is still missing, resulting in poor treatment 
90 outcomes and severe adverse effects of chemotherapy and radiotherapy (Brambilla and 
91 Gazdar, 2009). Susceptibility of lung to carcinogenesis is based on the metabolic imbalance 
92 between induction and detoxification pathways, with a significant role of external inducing 
93 factors (Hecht, 1999).
94 Polycyclic aromatic hydrocarbons (PAHs) produced by tobacco smoking are involved in 
95 the activation and development of lung cancer (Armstrong et al., 2004; Hecht, 1999). 
96 Although the detailed mechanism of how this group of carcinogens disrupts the 
97 homeostasis of lung cells is still unclear, studies have concluded that PAHs can induce the 
98 overexpression of cytochrome P4501A1 gene (CYP1A1), an important member of a large 
99 family of cytochrome P450 enzymes involved in the metabolism of PAHs (Shimada and 
100 Fujii-Kuriyama, 2004). Consequently, many highly electrophilic metabolic intermediates 
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101 can be produced, causing irreversible damage to human tissues and inducing cancer 
102 occurrence (Shimada and Fujii-Kuriyama, 2004). Therefore, targeting of CYP1A1 gene 
103 may be a promising therapeutic strategy especially for smoking-related lung cancer 
104 (Androutsopoulos et al., 2009; Bruno and Njar, 2007). The induction of CYP1A1 primarily 
105 occurs when the inducer binds to the ligand-activated transcriptional factor aryl 
106 hydrocarbon receptor (AhR) (Guigal et al., 2000). Flavonoid galangin, an antagonist 
107 against AhR, has been considered as an inhibitor candidate to decrease the CYP1A1 
108 expression (Ciolino and Yeh, 1999). However, multi-targeted properties of this drug may 
109 lead to non-specific inhibition of the other members of the P450 gene family (Murakami et 
110 al., 2008; Sak and Everaus, 2015), suggesting a better and specific strategy is needed to 
111 target CYP1A1 gene for therapeutic intervention and treatment of lung cancer. 
112 RNA interference (RNAi) is a gene silencing technology at the transcriptional level and 
113 works through specifically targeting mRNA via sequence-specific matches, resulting in 
114 degradation of the target mRNA (Agrawal et al., 2003). siRNA technology promises 
115 greater advantages over conventional drugs currently in the market for its high targeting 
116 selectivity and low toxicity; however, pharmacokinetic properties of siRNA are 
117 unpredictable and its cellular uptake is poor (Lorenzer et al., 2015). Accordingly, specific 
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118 siRNA-mediated silencing of CYP1A1 expression with improved kinetics and uptake by 
119 target cells is urgently warranted.  
120 As widely used vehicles in nucleic acid delivery, non-viral vectors such as cationic 
121 liposomes are much safer than viral vectors (Khurana et al., 2013). Furthermore, compared 
122 to polymeric vectors, cationic liposomes may offer higher transfection and greater 
123 biocompatibility (Ruozi et al., 2003). Novel cationic lipids conjugated with functional 
124 targeting groups may offer a great potential for use in the preparation of cationic liposomes 
125 ( Ruozi et al., 2003; Kim et al., 2010b; Sun et al., 2018). 
126 Liposomes manufactured using the traditional thin-film hydration technique with 
127 subsequent prepartion as liquid dispersions are unstable during storage owing to the 
128 liability of phospholipids to hydrolysis and oxidation, with subsequent compromise of the 
129 validity of liposomes as drug carriers (Grit and Crommelin, 1993). Alternatively, 
130 proliposomes are stable powdered phospholipid formulations prepared by coating 
131 carbohydrate carrier particles with thin phospholipid films using modified rotary 
132 evaporators (Elhissi et al., 2006; Gala et al., 2015). Liposomes can be generated from 
133 proliposomes via the addition of aqueous phase and shaking (Elhissi et al., 2006; Gala et 
134 al., 2015). Several reports have established the suitability of manufacturing thin-film-based 
135 proliposome powders on a large scale, for instance by using fluidized-bed coating (Chen 
136 and Alli, 1987; Kumar et al., 2001; Gala et al., 2015). Liposomes generated from lipid film 
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137 coated sugars (i.e. proliposomes) have been widely investigated for drug delivery. For 
138 example, early reports have shown that oral delivery of non-steroidal anti-inflammatory 
139 drugs in liposomes generated from proliposomes can protect against gastric ulceration in 
140 experimental animals (Katare et al., 1990). Proliposomes have also been investigated for 
141 nasal delivery of propranolol hydrochloride and nicotine (Ahn et al., 1995; Jung et al., 
142 2000a), and for parenteral administration of antifungal drugs (e.g. amphotericin B) (Payne 
143 et al., 1987), and anticancer agents such as methotrexate (Park et al., 1994) and doxorubicin 
144 (Wang et al., 2000), and for transdermal delivery of nicotine (Hwang et al., 1997; Jung et 
145 al., 2000b). We have previously shown that proliposomes made by coating sucrose with 
146 lipid films can generate inhalable liposomes when hydrated in situ within medical 
147 nebulizers (Elhissi et al., 2012). More recent investigators have shown that diltiazem HCL 
148 liposomes generated from proliposomes could be used for topical treatment of glioma 
149 (Mokhtar Ibrahim et al., 2013) and dermatitis (Jahn et al., 2014) using animal models. 
150 Proliposomes made by film-ciating of sugar particles have recently been demonstrated to be 
151 compressible into tablets, with properties being dependent on formulation (Khan et al., 
152 2018). 
153
154 In this study, lipid film-based proliposome technology was employed for the preparation of 
155 cationic liposomes-siRNA (CL-siRNA) formulations for targeting the CYP1A1 gene. AhR-
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156 mediated induced expression of CYP1A1 in A549 adenocarcinoma cell line was used to 
157 model smoking induction of CYP1A1 expression. The effects of CYP1A1 silencing with 
158 CYP1A1 CL-siRNA on CYP1A1 expression, CYP1A1enzyme activity, cell apoptosis and 
159 tumor spheroids formation were verified in induced A549 cell lines. The effect of CYP1A1 
160 silencing on tumor regression was further investigated in the induced A549 tumors in 
161 xenograft BALB/c-nude mice. 
162
163 2. MATERIALS AND METHODS
164
165 2.1. Materials
166 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and dioleoyl-
167 phosphatidylethanolamine (DOPE) were purchased from Avanti Polar-Lipids Inc. 
168 (Alabaster, AL, USA). Cholesterol was obtained from Biotech Co. Ltd (Shanghai, China), 
169 and 3-methylcholanthrene (3-MC) was purchased from SUPELCO Co. 
170 (Pennsylvania ,USA). Human CYP1A1 siRNA was chemically synthesized and purified 
171 via HPLC by RiboBio (Guangzhou, China). Goldview staining was purchased from 
172 Guangzhou Geneshun Biotech Ltd (Shanghai, China). RNA prep pure cell kit was 
173 purchased from TIANGEN (Beijing, China). The sequence for siRNA was as follows: 
174 siRNA against CYP1A1: sense, 5’-GGCCUGAAGAAUCCACCAG-3’; antisense, 3’-
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175 CUGGUGGAUUCUUCAGGCC-5’. FAM-siRNA and the same sequence was obtained 
176 from Sangon Biotech (Shanghai, China). Lipofectamine2000 was obtained from Invitrogen 
177 (USA).
178 2.2. Preparation of liposome-siRNA complexes using lipid-coated particulate-based 
179 proliposomes
180 Sorbitol particles (300-500 μm) were placed in 50 ml pear-shaped flask and attached to a 
181 modified rotary evaporator with a feed-line tube. The flask was partially immersed in a 
182 water bath (37°C). A chloroform solution containing DOTAP, DOPE and Cholesterol 
183 (3:4:3 mole ratio) was injected in portions (0.5 mL each) via the feed-line using a syringe 
184 and by releasing the vacuum for a few seconds using a valve fitted on top of the condenser 
185 to allow lipid solution to be drawn through the feed-line and be sprayed onto the sorbitol 
186 carrier particles. After each addition, complete evaporation of chloroform was allowed 
187 before injecting the next portion. After solvent was completely evaporated, the solid 
188 particles of proliposomes were collected and stored in glass vials in the freezer (-18⁰C). 
189 Proliposomes were hydrated with water to form liposomes (1 mg/mL) followed by probe-
190 sonication. The sonicated cationic liposomes (CL) were mixed with siRNA in RNase-free 
191 water using vortex-mixing and incubated for 30 min at room temperature to form CL-
192 siRNA complexes. 
193
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194 2.3.  Scanning electron microscopy (SEM) of lipid film coated proliposomes
195 Microparticles made by coating sorbitol carrier with lipid film were positioned onto a 
196 carbon pad (Agar Scientific, UK), and coated with a thin film of gold using the sputter 
197 coater of the microscope (Bio-Rad, England). The morphology of the resultant 
198 microparticles was investigated under vacuum using the Quanta 200 scanning electronic 
199 microscope.
200
201 2.4.  Size analysis and zeta potential studies of CL-siRNA
202 Size analysis and zeta-potential studies of CL and CL-siRNA complexes were conducted 
203 using Photon Correlation Spectroscopy (PCS) and laser Doppler velocimetry, respectively. 
204 The studies were performed using the Malvern ZetaSizer Nano ZS90 (Malvern Instruments 
205 Ltd, UK) upon selecting the right software for each type of analysis. Size and size 
206 distribution were expressed by the instrument as the mean hydrodynamic diameter and 
207 polydispersity index (PDI), respectively.
208
209 2.5.  Cell Culture Studies
210 Human alveolar adenocarcinoma, A549 lung cancer cell line was obtained from American 
211 Type Culture Collection (Rockville, MD, USA). A549 cell line was cultured in RPMI 1640 
212 medium (HyClone, USA) supplemented with 10% fetal bovine serum (Minhai, China), 100 
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213 U/ml penicillin, 100 mg/ml streptomycin. Cell culture was performed in an incubator 
214 maintained at 37⁰C in a humidified environment containing 5% CO2.
215
216
217 2.6.  Agarose gel retardation assay 
218 To confirm formation of the complexes, the agarose gel retardation assay was employed to 
219 select the optimal charge ratio between cationic liposomes and negatively charged siRNA. 
220 CL-siRNA complexes were prepared at various molar ratios, and then run through a 2% 
221 agarose gel. The mobility of siRNA complexed with cationic liposomes was visualized by 
222 GoldView staining. 
223
224 2.7.  RNase protection assay of siRNA in cationic liposome complexes
225 An ideal siRNA delivery system is expected to protect siRNA against RNase enzymatic 
226 degradation. In order to monitor siRNA degradation by nuclease, firstly, siRNA-CL 
227 complexes were prepared at a final siRNA concentration of 5 μM and then incubated in the 
228 presence of 0.1mg/ml RNase for 30 min at 37⁰C. An aliquot (20 μl) was removed and snap-
229 frozen at -80⁰C at every time point. All samples were thawed on ice when they were 
230 collected and immediately mixed with 5 μl of a 100 mM Triton X100 solution and 25 μl of 
231 RNA-extraction mixture (phenol/chloroform/isoamyl alcohol; 25:24:1). The siRNA was 
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232 precipitated with ethanol, electrophoresis was performed on agarose gel (2%) and 
233 visualization took place by GoldView staining (Buyens et al., 2008).
234
235
236 2.8.  Cell model with high expression of CYP1A1
237 For the purpose of simulating the gene induction pathway to obtain a cell model with high 
238 CYP1A1 gene expression, an induction assay was carried out on A549 cells which are 
239 common for CYP1A1 gene research (Fazili et al., 2010). Cells were seeded in 12-well 
240 plates at a density of 1×104 cells per well, followed by 24 h incubation at 37⁰C in a 
241 humidified environment containing 5% CO2, and cells were treated with 3-MC with a final 
242 concentration of 5 μM for further 24 h (3-MC was dissolved in DMSO). 3-MC is one of the 
243 most potent PAH carcinogens, which is usually used in the induction of CYP1A1 via the 
244 AhR mechanism (Abdelrahim et al., 2003). After the induction, the induced cells were 
245 collected and used in the subsequent experiments. 
246
247 2.9.  Cellular uptake of siRNA in induced A549 lung cancer Cells 
248 Transfection of FAM-siRNA (what is FAM-siRNA) was performed in induced A549 cells. 
249 The induced A549 cells were seeded at a concentration of 5×105 cells per well in six-well 
250 plates. The cells were grown to a confluency between 60% and 80% and washed with pre-
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251 warmed (37℃ ) PBS, and then they were incubated with 100 nM liposome-free FAM-
252 siRNA or 100 nM FAM-siRNA-liposome complexes in serum-free medium. Following 
253 incubation for 4 h, the medium was replaced and the cells were washed with PBS twice, 
254 and then analyzed using flow cytometry (Beckman Coulter, USA) and examined under a 
255 fluorescence microscope. siRNA complexed with Lipofectamine2000 (Lipo2000) was used 
256 as a positive control in the experiments.  
257  
258 2.10.  Silencing of 3-MC induced CYP1A1 gene in A549 lung cancer cell line
259 For evaluation of the mRNA of CYP1A1 gene in vitro and in vivo, RNA was extracted 
260 from cells 24 h after transfection with CYP1A1-specific siRNA (n = 3) or from A549 lung 
261 tumor (n = 3), respectively, using RNA prep Pure cell kit. cDNA was then obtained by 
262 reverse transcription of the total RNA using the TIANscript RT kit and the CYP1A1 (sense, 
263 5’-GGCCUGAAGAAUCCACCAG-3’; antisense, 3’-CUGGUGGAUUCUUCAGGCC-5’). 
264 mRNA levels were analyzed using the SosoFastTM EvaGreen Supermix on iCycler iQTM 5 
265 system (Bio-Rad, USA) and β-actin was used as internal control. The PCR reaction was 
266 conducted at 95°C for 3 min followed by 40 cycles of 95°C for 5 s, and 56°C for 10 s in the 
267 iQ™5 Real-Time PCR Detection System. The expression of CYP1A1 was analyzed and 
268 normalized using the 2ΔCt method relative to the expression of β-actin. 
269
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270 2.11. CYP1A1 enzyme assays
271 To further study the silencing effect of siRNA on CYP1A1, the enzyme activity as well as 
272 the content of CYP1A1 was assessed. The CYP1A1 enzyme activity was determined by 
273 Human CYP1A1 fluorescence quantitative detection kits (Genmed Scientifics INC.USA). 
274 The CYP1A1 enzyme content was measured using Human CYP1A1 ELISA kits (R&D 
275 systems, USA). Both assays were performed following the relevant suppliers’ instructions.
276
277 2.12. Apoptotic assays
278 To examine the interactions between CYP1A1 gene regulation and the induced growth of 
279 tumor cells, different groups were designed in the cell apoptosis experiment. Induced A549 
280 cells were treated with CYP1A1-specific siRNA (100 nM) or complexed with cationic 
281 liposome in serum-free medium for 4 h and then further incubated in fresh completed 
282 medium. Cells were washed with PBS and digested in trypsin for suspension after 
283 incubation for 48 h, followed by double staining with FITC-Annexin V and propidium 
284 iodide using the cell apoptotic analysis kit (Beyotime, China) following the manufacturer’s 
285 instructions. Flow cytometry was used for investigation of cell apoptosis (n = 3). Further 
286 studies were performed to investigate the apoptosis mechanism. Caspases are the critical 
287 proteins responsible for apoptosis. These proteins are classified as initiators or executioners 
288 depending on their point of entry into the apoptotic cascade. It has been confirmed that 
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289 there were two main apoptosis pathways mediated by caspases (Boatright and Salvesen, 
290 2003). Among all the family members in this pathway, caspase 3 was considered as the 
291 final executioner, and meanwhile, caspase 8 and caspase 9 are the key initiator proteins 
292 which exist in the extrinsic and intrinsic apoptotic pathways, respectively. The three 
293 caspases were firstly detected with Caspase Activity Assay Kits (Beyotime, China). 
294
295 2.13. Multicellular tumor spheroids (MCTSs) assays
296 Multicellular tumor spheroids (MCTSs) may provide an appropriate model to identify the 
297 drug effect in vitro for its similarity to the tumor formation in vivo (Friedrich et al., 2009). 
298 A549 cells were cultured in a modified tumor sphere medium. The medium is comprised of 
299 recombinant fibroblast growth factor (EGF) (10ng/ml), basic fibroblast growth factor 
300 (bFGF) (10ng/ml) and insulin (4U/L), and plated at a density of 2×103 cells per well in 6-
301 well plates. Spheres were formed after 8-10 days incubation. After 24 h 3-MC induction, 
302 spheres were treated with different groups of siRNA which were described in the gene 
303 silence study at a siRNA final dose of 100 nM for 4 h. After further 72 h incubation, the 
304 results were observed by microscope. 
305
306 2.14. In vivo efficacy of targeting CYP1A1 gene using liposomes generated from lipid 
307 film-coated proliposomes
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308 The animal study protocol was approved by Institutional Animal Care and Use Committee 
309 of the Sichuan University in China. Male BALB/c nude mice (weighing 20-23 g) were used 
310 to investigate the antitumor efficacy of targeting CYP1A1 gene in vivo. Briefly, 1×107 
311 A549 cells were re-suspended in 200 µl serum-free RPMI 1640 medium and injected 
312 subcutaneously into the right flank of the nude mice. After 5 weeks tumor-bearing mice 
313 were randomly divided into four treatment groups (5 animals each). At days 1, 4, 7, 10, 13 
314 and 16, mice were intratumorally injected with 100 µl 10% 3-MC solution. Then at days 2, 
315 5, 8, 11, 14 and 17, mice were intratumorally injected again but with PBS, free siRNA or 
316 CL-siRNA. Every treatment was based on the dose of 40 µg siRNA per mouse. Calipers 
317 were used in this work to measure the tumor progression of every mouse. Tumor volumes 
318 were calculated as length×width×width×0.5(mm3). At the day 18, three animals from each 
319 group including control were sacrificed, and the tumors were excised. The measurements of 
320 CYP1A1 gene silencing effect were conducted as described earlier. 
321
322 2.15. Statistical analysis
323 Values were presented as mean (± SD) unless otherwise stated. The differences between 
324 groups were analyzed using the Student’s t-tests and one-way analysis of variance 
325 (ANOVA) with Bonferroni tests for multiple-group analysis. A probability level of P < 
326 0.05 was considered to indicate significant difference between the groups. 
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327
328
329
330 3. RESULTS
331 3.1.  Physical characterization of proliposomes, cationic liposomes (CL) and CL-
332 siRNA complexes
333 The surface morphology of proliposome powders prepared through coating sorbitol 
334 particles with lipid film was examined by scanning electron microscopy (SEM) (Figure 1). 
335 The high porosity of sorbitol (Figure 1a) facilitated coating of the lipid on the carrier 
336 surfaces (Figure 1b). Our SEM observations using cationic lipids to coat sorbitol particles 
337 is in concordance  with the previous findings using neutral lipids such as 
338 dimyristoylphosphatidylcholine coated onto sorbitol particles (Payne et al., 1986). Our 
339 study also further confirms that sorbitol is a highly suitable carrier for coating with lipid 
340 films and preparation of proliposomes because of its microporous structure. In another 
341 study, we demonstrated that the film coating proliposome technology can be scaled up 
342 using fluid-bed coating equipment that can deposit a lipid film on carbohydrate particles 
343 (e.g. sucrose), generating liposomes that can successfully entrap conventional small 
344 molecules, such as the antiasthma steroid beclometasone dipropionate (Gala et al., 2015). In 
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345 the present investigation, through a smaller scale of manufacturing using a modified rotary 
346 evaporator equipped with a feed tubeline, proliposomes made by coating sorbitol with 
347 cationic lipids were prepared. Upon hydration (including or excluding siRNA) and probe-
348 sonication, cationic liposomes were generated. The measured size of the siRNA-free 
349 vesicles was as small as 85±3.2 nm and the size distribution, expressed by PDI, was as low 
350 as 0.165. The uniform coating of sorbitol particles (Figure 1b) justifies the facilitated 
351 generation of liposomes in the nano-size range and the narrow size distribution (i.e. low 
352 PDI) (Figure 1d). Transmission electron microscopy (TEM) images confirmed the uniform 
353 round shape of the gene-free cationic liposomes, which were also similar to those 
354 incorporating siRNA, suggesting that the genetic material was complexed with the 
355 liposomes, with no apparent formation of siRNA aggregates (Figure 1c). 1,2-dioleoyl-3-
356 trimethylammonium-propane (DOTAP) in the formulation conferred the liposomes with a 
357 positive surface charge of about +43 mV (sorbitol solution pH=7.5) (Figure 1d). For 
358 formulations incorporating siRNA, the integrity of siRNA was studied (Figure 1e). Varying 
359 charge ratios of CL to siRNA (N/P ratio) were prepared at fixed siRNA concentration (100 
360 nM). With the N/P ratio higher than 4, the migration of siRNA was completely retarded, 
361 indicating good binding efficiency of CL with siRNA and successful formation of the 
362 complexes (Figure 1e, f). On the other hand, size and zeta potential of CL-siRNA 
363 complexes were 90 nm and +30 mV, respectively at the N/P mole ratio of 4:1 (Figure 1d), 
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364 which contributed to the good dispersion properties and stability of CL-siRNA complexes. 
365 Considering all the results above, N/P = 4:1 was chosen as the optimal charge ratio for CL-
366 siRNA complex formation.
367
368 Agarose gel assay is an established technique for checking the formation of complexes 
369 between liposomes and genetic materials (e.g. siRNA) (Kim et al., 2010a). To assess the 
370 ability of liposomes to protect siRNA from degradation, the stability of siRNA in RNase 
371 solution was tested. As shown in Figure 1f, free siRNA was completely degraded upon 
372 exposure to RNase. By contrast, when siRNA was incorporated into cationic liposomes, the 
373 genetic material was intact for at least 4 h, indicating that liposomes have provided short-
374 term protection for siRNA against enzymatic degradation. In this study, we made powdered 
375 cationic formulations of proliposomes by film coating the sorbitol sugar with cationic lipid. 
376 This can readily generate liposomes complexing with siRNA via addition of aqueous phase 
377 and sonication just on the day of administration; hence, storage instability of liposome 
378 dispersions is avoided.
379
380 3.2.  Stimulation of CYP1A1 gene expression by 3-MC treatment in A549 lung cancer 
381 cell line
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382 After incubation with 3-MC (5 μM) for 24 h, the induced A549 cells were collected to 
383 investigate the target gene CYP1A1 expression level. All samples were analyzed by RT-
384 PCR, which suggested that the mRNA level of CYP1A1 in induced cells was about 7 times 
385 higher than that in the normal cells. Enhanced CYP1A1 expression was maintained for at 
386 least 48 h after single induction. 
387
388 CL were compared with Lipo2000, a commonly used positive control for siRNA delivery, 
389 for evaluation of the siRNA delivering ability. FAM-labeled siRNA was prepared alone or 
390 mixed with CL or Lipo2000 at a final concentration of 100 nM. Both flow cytometry and 
391 confocal microscopy were used to investigate the uptake efficiency of the liposomes in 
392 A549 cells. The results indicated that both CL and Lipo2000 effectively delivered siRNA to 
393 cells (Figure 2a), and significantly improved the uptake efficiency compared with free 
394 siRNA solution (Figure 2b).
395
396 3.3.  Silencing of CYP1A1 gene expression in A569 lung cancer cell line
397 Transfection of induced A549 cells with CL-CYP1A1-siRNA caused a 7-fold down-
398 regulation of CYP1A1 gene expression. Similar results were obtained with transfection 
399 using CYP1A1-siRNA Lipo2000 control. On the other hand, free (i.e. naked) CYP1A1-
400 siRNA and negative control siRNA (NC siRNA) did not show any marked silencing effect 
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401 on CYP1A1 gene expression (Figure 3a). All agents were tested in the induced cells, and 
402 the unstimulated A549 cells were used as a negative control. The silencing effects of CL-
403 CYP1A1-siRNA on CYP1A1 protein levels and enzymatic activity was also seen (Figure 
404 3b and 3c), confirming successful retardation of gene expression target. CL-siRNA 
405 prepared using the film-coating proliposome technology caused a similar knockdown 
406 efficiency compared to the positive control Lipo2000. This clearly demonstrates that the 
407 facile approach of generating CL-siRNA using the proliposome technology was successful 
408 at providing a more stable powdered formulation than conventional liposomes. It was also 
409 capable of retarding the gene expression in levels similar to those of the established 
410 Lipo2000 transfection reagent.  
411
412 3.4.  Knockdown of CYP1A1 gene induces apoptotic cell death in 3MC- treated A549 
413 cells 
414 The number of apoptotic cells was quantified by FITC-Annexin V and propidium iodide 
415 (PI) double-staining. CL-siRNA triggered apoptosis in induced A549 cells (Fig.4a). 3-MC 
416 induced cells without further treatment were used as the negative control in these 
417 experiments in order to eliminate the inducer influence on the results. Findings revealed 
418 that 3-MC induction had a little impact on the cellular growth, whereas the induced cells 
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419 tended to undergo apoptosis with CYP1A1 silencing through the intrinsic apoptotic 
420 pathway marked by elevated caspase 3 and caspase 9, but not caspase 8, activities (Figure 
421 4B), also confirmed by direct immunostaining (data not shown). 
422
423 3.5.  The Effect of CYP1A1 gene silencing on sphere formation in A549 lung cancer 
424 cell line
425 Sphere formation assay was performed to investigate the effect of CYP1A1 silencing on 
426 formation of spheroid colonies in vitro. Untreated induced A549 cells successfully 
427 produced spheroid colonies when cultured in a modified tumor sphere medium. On the 
428 other hand, spheres treated with CYP1A1 siRNA delivered by cationic liposomes or 
429 Lipo2000 formulation showed a suppressive effect on the formation of sphere colonies. The 
430 other groups including those untreated and mock did not exhibit this effect (Figure 5).
431
432 3.6.  Antitumor efficacy of gene silencing of CYP1A1 in tumor-bearing nude mice 
433 using particulate-based proliposome technology 
434 In order to investigate the impact of CYP1A1 silencing on tumor progression in vivo, we 
435 determined the antitumor efficacy of CL-siRNA in A549 xenograft nude mice model 
436 (Figure 6a). Results showed that growth rate of tumor with cationic liposome or Lipo2000 
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437 was significantly slower than that observed in the control groups including animals injected 
438 with PBS or naked (free) siRNA (Figure 6b/c). Moreover, the treatment caused down-
439 regulation of the expression of CYP1A1 gene in the tumors as detected by RT-PCR on the 
440 third day after giving the intratumoral dose (Figure 6d). Thus, the reduction of CYP1A1 
441 gene in induced A549 cells mediated by siRNA gave a significant tumor growth inhibition.
442
443 4. DISCUSSION 
444 In this study we report that liposome-based gene delivery technology is a viable and stable 
445 approach for targeting the cancer causing gene CY1PA1. A major issue for liposomes is 
446 their instability as liquid dispersion, commonly when prepared using the thin-film 
447 hydration technique (Grit and Crommelin, 1993). This was overcome in the present study 
448 by using the film-coating proliposome technology to prepare powdered lipid formulations 
449 that, when needed, can be used to generate CL-siRNA complexes.  
450 This technology, as demonstrated in our study, can potentially be considered for therapeutic 
451 intervention and treatment of lung cancer, one of the most common types of cancer and a 
452 leading cause of death (Torre et al., 2015). This approach comes as part of ongoing efforts 
453 to ameliorate the outcomes related to the undesirable pharmaceutical, pharmacokinetic and 
454 pharmacodynamic properties of lung cancer drugs, such as solubility, toxicity, stability, and 
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455 lack of selective effect on the cancerous cells (Tiwari et al., 2012). These properties can be 
456 enhanced by using drug vectors that are highly biocompatible and biodegradable 
457 (Zarogouldis et al., 2012). 
458 Continuous exposure to tobacco smoking can induce the expression of CYP1A1,  a  gene 
459 present in extra hepatic tissues (Androutsopoulos et al., 2009), that is involved in the 
460 metabolic activation of PAH produced from tobacco smoking. After the induction, high 
461 CYP1A1 gene expression can contribute to the carcinogenic derivatives production and 
462 may initiate neoplastic transformation (Whitlock, 1999). Stimulated bronchial epithelial 
463 cells express high levels of CYPT1A1 gene when induced by tobacco or environmental 
464 pollutants, predisposing them to lung cancer (Mercer et al., 2006). Hence, A549 human 
465 alveolar basal epithelial cell line represents a valuable model for the mechanistic studies 
466 involving induction of the pulmonary CYP system (Giard et al., 1973). In this study, we 
467 constructed a cell model on the basis of AhR mechanism through which CYP1A1 can be 
468 activated to a high level using 3-MC as previously reported (Hukkanen et al., 2000). In the 
469 induced cells, a high CYP1A1 gene expression was observed, similar to that seen in 
470 cancerous cells exposed to air contaminants. In our study, the 3-MC concentration was 
471 optimized to exhibit low toxicity and relatively high induction efficiency. 
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472 Limited studies have reported the relationship between inhibition of CYP1A1 gene and 
473 lung cancer therapy (Androutsopoulos et al., 2009). Flavonoid (such as quercetin), for 
474 example, was previously reported to inhibit CYP1A1 induction (Ciolino and Yeh, 1999). In 
475 the present work, we used RNAi as the inhibition strategy in lung cancer cells. Successful 
476 therapy using siRNA depends on effective delivery and protection against RNase. Owing to 
477 its large molecular weight and anionic nature, the uptake of siRNA by cancer cells is very 
478 poor, making the use of appropriate delivery systems highly advantageous (Gala et al., 
479 2015). To overcome these issues, we prepared cationic liposomes via the lipid-coating 
480 proliposome technology shown previously to be suitable for large scale production (Gala et 
481 al., 2015). Using fluidized bed coating, the solid proliposomes produced can be stored at -
482 18°C until needed for subsequent generation of liposomes, providing stability for several 
483 months (data not shown). In addition mass production and storage stability of proliposomes 
484 (as liposome precursors), the cationic liposomes were able to protect siRNA from nucleases 
485 and facilitated efficient transportation of siRNA into the cytoplasm, resulting in gene 
486 silencing effects similar to those exhibited by the commercially established Lipo2000. 
487 Indeed, both our in vitro and in vivo results indicated that CYP1A1 gene silencing by 
488 siRNA can regulate the cancer in the induced cells. Our data showed that the down-
489 regulation of CYP1A1 gene induced cellular apoptosis and interfered with the formation of 
490 tumor spheres in vitro and inhibited tumor development in BALB/c nude xenograft model. 
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491 Various murine models were established for the evaluation of novel therapeutics and 
492 examination of the molecular mechanisms underlying transformation, invasion and 
493 metastasis (Kellar et al., 2015). The A549 xenograft model was chosen in this study for the 
494 convenience of tumor measurement by making the cancer cells readily accessible (Kellar et 
495 al., 2015). Therefore in vivo results remain preliminary in nature and inconclusive. 
496 However, the emerging data confirm the validity of CL-siRNA-CYP1A1 as a proof of 
497 concept for targeting lung cancer, future experiments will explore different experimental 
498 designs including optimizing dosage and scheduling regimen to improve efficacy.
499
500 5. CONCLUSION
501 This study has shown that CYP1A1 gene can be a potential target for treatment of lung 
502 cancer. Cationic liposomes generated from film-coated proliposomes provided excellent 
503 siRNA carriers, with subsequent ability to silence the CYP1A1 gene both in vitro and in 
504 vivo. Further investigations to evaluate the aerosolization properties of CL-siRNA in animal 
505 models using the proliposome approach are warranted. This study will open the doors to 
506 further investigations in multiple therapeutic directions in the field of drug delivery and 
507 cancer treatment. 
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697 FiGURE LEGENDS
698
699 FIGURE 1. Characterization of lipososome-siRNA complex. (a) Scanning electron 
700 microscopy images of blank sorbitol and (b) Image of proliposome particles after coating 
701 with the lipid. (c) Transmission electron microscopy image of cationic liposomes generated 
702 from proliposomes. (d) Size and zeta potential of CL-siRAN complex at different cationic 
703 liposome to siRNA ratios. (e) The mobility of siRNA complexed with cationic liposomes at 
704 various molar ratios, ranging from 1-10 liposome to siRNA, by agarose gel retardation 
705 assay visualized by Goldview staining. (f) Stability of CL-siRNA complex against RNase. 
706 Cationic liposomes were complexed with siRNA at different molar ratios to study the 
707 degradation of siRNA by RNase by incubation with RNase at 37⁰C for up to 6 hours. The 
708 CL and siRNA N/P ratio was kept 4:1 in all samples and siRNA alone was used as negative 
709 control. 
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710
711 FIGURE 2. Cellular uptake of CL-siRNA by A549 lung cancer cell line. (a)  
712 Representative images of A549 cells transfected with FAM-siRNA, CL-FAM-siRNA or 
713 Lipo2000-FAM-siRNA. Cells were treated with 5 μM 3-MC to induce CYP1A1 expression 
714 then incubated either with 100 nM liposome-free FAM-siRNA or 100 nM FAM-siRNA-
715 liposome complexes in serum-free medium. After transfection, cells were stained with 4’6-
716 diamidino-2-phenylindole (DAPI) and fluorescence images were taken by confocal 
717 microscope. (b) The cellular uptake efficiency of CL-siRNA in the induced cells was also 
718 measured by flow cytometry (n=3). 
719
720 FIGURE 3. Targeting of CYP1A1 gene using gene silencing approach. A549 lung 
721 cancer cells were treated with 3-MC then transfected with CYP1A1-siRNA using liposome 
722 (CL/siRNA) or Lipofectomine 2000 (Lipo2000/siRNA). Non-stimulated A549 cells were 
723 used as a negative control whereas 3-MC stimulated A549 transfected with naked siRNA 
724 were used as a positive control. (a) Expression of CYP1A1 gene of was analyzed by 
725 quantitative RT-PCR using β-actin as internal control. Data are shown as normalized fold 
726 expression relative to the untreated control (n = 3), * p<0.05. (b) CYP1A1 enzyme activity 
727 was measured by Human CYP1A1 enzyme activity fluorescence quantitative detection kits 
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728 (n=3), * p<0.05. (c) CYP1A1 enzyme content was detected with Human CYP1A1 ELISA 
729 kits (n=3), *p<0.05.  
730
731 FIGURE 4. Knockdown of CYP1A1 gene causes apoptosis in lung cancer cells. (a) 
732 A549 lung cancer cells were treated with 3-MC for 24 hours then transfected with CL-
733 CYP1A1-siRNA or CYP1A1 lipofectamine-2000. Cells were then stained with flourescein-
734 conjugated annexin-V and propidium iodide (PI) and analyzed by flow cytometry. 
735 Percentages of apoptotic cells are presented as mean ± SD (n = 3). (b) Quantification of the 
736 active caspase 3, caspase 8 and caspase 9 in 3-MC-induced A549 lung cells transfected 
737 with CL- CYP1A1-siRNA as performed by Flow Cytometry using caspase activity assay 
738 kits as described in the methods section. Data are presented as mean ± SD (n = 3). 
739
740 FIGURE 5. Effect of CYP1A1 gene silencing on A549-mediated spheroid colonies. 
741 Spheroid colonies were generated as described in the methods section. Sphere cells were 
742 treated with 3-MC for 24 h and subsequently then transfected with CL-CYP1A1-siRNA or 
743 CYP1A1 lipofectamine-2000 for 72 h. Representative images shown are from three 
744 different experiments. 
745
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746 FIGURE 6. Inhibition of tumor growth using CYP1A1-siRNA in mouse model system. 
747 BALB/c-nude mice were injected with 10 million A549 cells in serum free medium 
748 subcutaneously into right flank. The tumor bearing mice were divided into four treatment 
749 group (n=5). (a) All mice were injected with 3-MC and after 10 days were treated with (i) 
750 PBS (ii) CL-CYP1A1-siRNA (iii) Naked-siRNA and (iv) Lipofectamin-complxed 
751 CYP1A1-siRNA. (b) The volume of each tumor was measured at the indicated time points 
752 as described in methods. Results are expressed as mean, (n = 5), ± SD. (c) Mice were 
753 sacrificed after 18 days with six intratumoural injection of CYP1A1 siRNA and images of 
754 each tumors were taken as shown (n=5). (d) Total RNA were isolated from tumor of each 
755 mice. Expression of CYP1A1 gene were quantified by RT-PCR (Data expressed as mean ± 
756 SD; n=3).
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